Medical organizational model for prevention of cardiovascular complications in patients with atrial fi brillation based on clinical physiological assessment of risk factors

Introduction. Improving the prevention of cardiovascular complications (CVC) is an actual problem. Clinical physiological analytics (CPA) provides an evidence basis for selecting a personalized model prevention ov CVC.
Purpose: тo develop a medical organizational model for prevention of cardiovascular complications (CVC) in patients with atrial fibrillation (AF) based on the CPA of risk factors (RF).
Material and methods. A multicenter research was in period 2017–2026. The research subjects — patients with AF (n = 421), average age of 63 ± 4.2 years. The main research group (n = 303) included patients with paroxysmal AF during periods between paroxysms. The control group (n = 118) included patients with persistent AF after restoration of sinus heart rhythm using: electrical impulse therapy — control group №1 (n = 67) and thermal ablation of the pulmonary vein orifices — control group №2 (n = 51). The research objectives were the prevalence of CVC RF, the process components of a medical organizational model for CVC prevention in patients with AF, and the medical social effectiveness of the model. The follow-up period of patients was 12 months. Research methods included literature review, statistical analysis, clinical physiological analysis, systematization and comparative analysis.
Results. RF of CVC in patients with AF (more than 80% of patients in the group), with no significant differences between groups, included arterial hypertension, cardiac arrhythmia such as sinus tachycardia and extrasystole, chronic heart failure (CHF), and dorso- and cervicopathy. Compared to the control group, the main research group had significantly fewer patients with low physical activity (9% vs. 74.6%, p = 0.001) and frequent alcohol consumption (27% vs. 47%, p = 0.01). The process components of the medical organizational model for CVC prevention include a comprehensive patient-centered approach based on clinical management technology and artificial intelligence, clinical physiological analytics of the CVC RF. The proportion of patients with recurrent AF was 2% in the main group, 5% in control group №1, and 11% in control group №2. The increase in the proportion of adherent primary care patients over 12 months averaged 389%, with no significant difference between the groups. Stroke, myocardial infarction, death, or gastrointestinal bleeding were not identified in the all groups. The proportions of patients with CHF progression in the main and control groups after 12 months of follow-up were 3% and 13.56%, respectively (p = 0.025).
Conclusion. Adherence of patients to primary care and cardiovascular prevention model based on the CFA FR contributed to a low rate of AF recurrence after successful restoration of sinus heart rhythm and progression of CHF, as well as the effective prevention of adverse clinical cardiovascular outcomes.

1. Weible ER. The future of physiology. Human Physiology. 1998;24(4):5 (In Russian).

2. Ma Q, Zhu J, Zheng P, Zhang J, Xia X, Zhao Y. Global burden of atrial fi brillation/fl utter: Trends from 1990 to 2019 and projections until 2044. Heliyon. 2024;10:e24052. doi: 10.1016/J.HELIYON.2024.E24052

3. Vinter N, Cordsen P, Johnsen S, Staerk L, Benjamin E, Frost L. Temporal trends in lifetime risks of atrial fi brillation and its complications between 2000 and 2022: Danish, nationwide, population-based cohort study. BMJ. 2024;385:e077209. doi: 10.1136/bmj-2023-077209

4. Kalarus Z, Mairesse G, Sokal A, Boriani G, Średniawa B, Casado-Arroyo R. Searching for atrial fi brillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper. EP Eur. 2023;25:185–198. doi: 10.1093/europace/euac144

5. Muromtseva GA, Shalnova SA, Yavelov IS, Ievlev RV, Maksimov SA, Kapustina AV, Balanova Yu.A., Evstifeeva SE, Imaeva AE, Yarovaya EB, Drapkina OM. Population portrait of atrial fi brillation according to ESSE-RF data. Preventive medicine. 2025;28(11):7–13 (In Russian).

6. Liu S, Tan Y, Huang Ц, Luo H, Pan В. Wu S. Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. Seminars in Arthritis and Rheumatism.2024;Vol.64,152304. doi: 10.1016/j.semarthrit.2023.152304

7. Hu Z, Ding L, Yao Y. Atrial fi brillation: mechanism and clinical management. Chin Med J. 2023;136:2668–2676. doi: 10.1097/CM9.0000000000002906

8. Hu D, Barajas-Martinez H, Zhang Z, Duan H, Zhao Q, Bao M, Du Y, Burashnikov A, Monasky M, Pappone C, Huang C, Antzelevitch C, Jiang H. Advances in basic and translational research in atrial fi brillation. Philos Trans R Soc Lond B Biol Sci. 2023;19;378(1879):20220174. doi: 10.1098/rstb.2022.0174

9. Voskoboinik A, Kalman J, Anurica de Silva, Nicholls T, Costello B, Nanayakkara S, et al. Alcohol abstinence in drinkers with atrial fi brillation. N Engl J Med. 2020;382:20–28. doi: 10.1056/NEJMoa1817591

10. Garnvik L, Malmo V, Janszky I, Ellekjær H, Wislоff U, Loennechen J, Nes B. Physical activity, cardiorespiratory fi tness, and cardiovascular outcomes in individuals with atrial fi brillation: the HUNT study. Eur Heart J. 2020;41(15):1467–1475. doi: 10.1093/eurheartj/ehaa032

11. Tatangelo M, Rebecchi M, Sgueglia M, Colella A, Crescenzi C, Panattoni G. The complex but fascinating relationship between sport and atrial fi brillation: from pathophysiology to the clinical scenario. J Cardiovasc Dev Dis. 2023;10: 255. doi: 10.3390/jcdd10060255

12. Wingerter R, Steiger N, Burrows A, Estes N. Impact of Lifestyle Modifi cation on Atrial Fibrillation. Am. J. Cardiol. 2020;125:289–297.

13. Soliman E, Rahman A, Zhang Z, Rodriguez C, Chang T, Bates J. Eff ect of intensive blood pressure lowering on the risk of atrial fi brillation. Hypertension. 2020;75:1491–1496. doi: 10.1161/HYPERTENSIONAHA.120.14766

14. Wang A, Green J, Halperin J, SrPiccini J. Atrial fi brillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74:1107–1115. doi: 10.1016/j.jacc.2019.07.020

15. Gordon IB, Gordon AI. Cerebral and peripheral disorders in clinical cardiology. Moscow: Meditsina. 1994. 160 p. (In Russian).

16. Goloshchapov-Aksenov RS, Bagin SA, Koledinsky AG, Rukodaynyy OV. Practicum of clinical management. Moscow: RUDN University, 2025. 95 p. (In Russian).

17. Goloshchapov-Aksenov RS, Koledinsky AG, Fomina AV, Kicha DI, Rukodaynyy OV, Bagin SA. Clinical and physiological analytics in the management of stable hypertension (using elderly patients as an example). In: Vocal function: a dialogue between specialists (ISCPP2025). Abstracts of the III Congress of the International Society of Clinical Physiology and Pathology. Moscow — Herceg Novi — Caracas, 2025. 115–117. (In Russian).

18. National Standard of the Russian Federation GOST R 59921.9- 2022 «Artifi cial Intelligence Systems in Clinical Medicine. Data Analysis Algorithms in Clinical Physiology.” Approved and put into eff ect by Order of the Federal Agency for Technical Regulation and Metrology dated October 18, 2022, No.1144-st. https://base.garant.ru/406583621/ (In Russian).

19. Federal Law dated June 29, 2015, No. 162-FZ “On Standardization in the Russian Federation.” https://www.consultant.ru/document/cons_doc_LAW_181810/ (In Russian).

20. Clinical guidelines “Atrial Fibrillation and Flutter in Adults — 2020-2021-2022 (June 10, 2021)”. https://disuria.ru/_ld/11/1114_kr20I48MZ.pdf (In Russian).

21. Clinical guidelines “Atrial Fibrillation”. 2025. https://old.scardio.ru/content/Guidelines/2025/КР%20Фибрилляция_трепетание_предсердий%2002.09.25_рамка.pdf (In Russian).